{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:15Z","timestamp":1791868935038,"version":"4.3.4"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Nivolumab has been associated with immune\u2010related adverse events, including nephritis, with acute interstitial nephritis being the most commonly reported renal manifestation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case<\/jats:title><jats:p>We describe the first case to our knowledge of minimal change disease with nephrotic syndrome associated with the PD\u20101 checkpoint inhibitor, Nivolumab. Minimal change disease has been reported with other immune checkpoint inhibitors; however, this is the first reported case with Nivolumab. We report development of nephrotic syndrome with acute kidney injury in a 57\u2010year\u2010old man, 1\u2009month after commencement of Nivolumab for metastatic squamous cell carcinoma of the tongue. Minimal change disease was confirmed by renal biopsy. Management with corticosteroids and cessation of Nivolumab failed to improve kidney function or nephrosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case adds to current literature identifying minimal change as an additional complication of immune checkpoint inhibitor\u2010associated acute kidney injury. Given the increasing use of immune checkpoint inhibitors for a range of malignancies, nephrologists, oncologist and generalists should be aware of the spectrum of kidney pathologies associated with their use.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1250","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T02:42:35Z","timestamp":1593484955000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?"],"prefix":"10.1002","volume":"3","author":[{"given":"Erin","family":"Vaughan","sequence":"first","affiliation":[{"name":"Renal Department Royal Prince Alfred Hospital, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-3728","authenticated-orcid":false,"given":"Elizabeth","family":"Connolly","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Chris O Brien Lifehouse, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mun","family":"Hui","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Chris O Brien Lifehouse, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Chadban","sequence":"additional","affiliation":[{"name":"Renal Department Royal Prince Alfred Hospital, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2980"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00080"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy105"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0478-8"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000455014"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018050488"},{"issue":"6","key":"e_1_2_8_9_1","first-page":"936","article-title":"Renal effects of immune checkpoint inhibitors","volume":"32","author":"Izzedine H","year":"2016","journal-title":"Nephrol Dial Transpl"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0848-y"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.358"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0408-2"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9814-17"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000189"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.11.028"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.04.026"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2718-y"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0958-6"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.484"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0959.1000119"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcnr2.1250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.1250","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:52:50Z","timestamp":1693810370000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1002\/cnr2.1250"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1250","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"2019-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1250"}}